Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB2 | P05107 | 1/20 | 0.33 |
| ▸ | ICAM1 | P05362 | 1/20 | 0.33 |
| ▸ | ITGAL | P20701 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 3/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | AR | P10275 | 3/20 | 0.32 |
| ▸ | MAOA | P21397 | 1/20 | 0.31 |
| ▸ | MAOB | P27338 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.30 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19345008 | 0.86 | AR (0.34) | LMNAALDH1A1HPGDMAPK1SMN1; SMN2 | |
| SCHEMBL19340284 | 0.85 | PDK2 (0.35) | ITGB2ICAM1ITGALLMNAALDH1A1 | |
| SCHEMBL19344954 | 0.84 | TSHR (0.34) | ITGB2ICAM1ITGALLMNASMN1; SMN2 | |
| SCHEMBL19344965 | 0.83 | AR (0.37) | LMNAALDH1A1HPGDMAPK1SMN1; SMN2 | |
| SCHEMBL19340280 | 0.82 | PGR (0.39) | ITGB2ICAM1ITGALLMNAMAPK1 | |
| SCHEMBL20353203 | 0.81 | OPRM1 (0.37) | LMNAALDH1A1SMN1; SMN2KDM4EOPRM1 | |
| SCHEMBL19340273 | 0.80 | PGR (0.33) | LMNA | |
| SCHEMBL18411320 | 0.79 | SMN1; SMN2 (0.33) | ALDH1A1MAPK1SMN1; SMN2KDM4E | |
| SCHEMBL13143204 | 0.79 | PGR (0.45) | LMNAMAOAMAOBOPRM1OPRL1 | |
| SCHEMBL18411325 | 0.78 | KDM4E (0.31) | KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170263871-A1 | ORGANIC ELECTROLUMINESCENT MATERIAL AND ORGANIC OPTOELECTRONIC DEVICE | TIANMA MICRO-ELECTRONICS CO., LTD. (CN) | 2017-09-14 | — | — | US | disclosed |
| US-20170263871-A1 | ORGANIC ELECTROLUMINESCENT MATERIAL AND ORGANIC OPTOELECTRONIC DEVICE | TIANMA MICRO-ELECTRONICS CO., LTD. (CN) | 2017-09-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170263871-A1 | ORGANIC ELECTROLUMINESCENT MATERIAL AND ORGANIC OPTOELECTRONIC DEVICE | OR10J3, RPS10, OR51E2 | ITGB2 49/4885ICAM1 296/4885ITGAL 34/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.